131 related articles for article (PubMed ID: 21447613)
1. Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding.
André P; DeGuzman F; Haberstock-Debic H; Mills S; Pak Y; Inagaki M; Pandey A; Hollenbach S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Jul; 338(1):22-30. PubMed ID: 21447613
[TBL] [Abstract][Full Text] [Related]
2. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA;
Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
Collet JP; O'Connor S
Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
7. Elinogrel, an orally and intravenously available ADP-receptor antagonist. How does elinogrel affect a personalized antiplatelet therapy?
Müller KA; Geisler T; Gawaz M
Hamostaseologie; 2012; 32(3):191-4. PubMed ID: 22772894
[TBL] [Abstract][Full Text] [Related]
8. Thienopyridines and other ADP-receptor antagonists.
Bernlochner I; Sibbing D
Handb Exp Pharmacol; 2012; (210):165-98. PubMed ID: 22918731
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
Leonardi S; Rao SV; Harrington RA; Bhatt DL; Gibson CM; Roe MT; Kochman J; Huber K; Zeymer U; Madan M; Gretler DD; McClure MW; Paynter GE; Thompson V; Welsh RC
Am Heart J; 2010 Jul; 160(1):65-72. PubMed ID: 20598974
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
11. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Serebruany VL; Sibbing D; DiNicolantonio JJ
Cardiology; 2014; 127(1):20-4. PubMed ID: 24192670
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
13. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z
Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
15. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel.
Serebruany VL
Thromb Haemost; 2012 Dec; 108(6):1024-7. PubMed ID: 23070029
[TBL] [Abstract][Full Text] [Related]
16. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
17. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.
Hashimoto M; Sugidachi A; Isobe T; Niitsu Y; Ogawa T; Jakubowski JA; Asai F
Biochem Pharmacol; 2007 Oct; 74(7):1003-9. PubMed ID: 17681285
[TBL] [Abstract][Full Text] [Related]
18. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
Varenhorst C; James S; Erlinge D; Braun OO; Brandt JT; Winters KJ; Jakubowski JA; Olofsson S; Wallentin L; Siegbahn A
Am Heart J; 2009 Mar; 157(3):562.e1-9. PubMed ID: 19249429
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Storey RF
Thromb Haemost; 2011 May; 105 Suppl 1():S75-81. PubMed ID: 21479343
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
